What Are Wall Street Analysts' Target Price for Humana Stock?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 16 2025
0mins
Source: NASDAQ.COM
Company Overview and Performance: Humana Inc. has a market cap of $27.8 billion and provides medical and specialty insurance products, but its stock has underperformed significantly, declining 34.5% over the past year compared to an 11.5% rise in the S&P 500 Index.
Analyst Ratings and Expectations: Despite recent challenges, analysts maintain a "Moderate Buy" consensus on HUM stock, with expectations for EPS growth and price targets suggesting potential upside of up to 49% from current levels.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TFC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TFC
Wall Street analysts forecast TFC stock price to rise
17 Analyst Rating
10 Buy
6 Hold
1 Sell
Moderate Buy
Current: 49.300
Low
50.00
Averages
55.93
High
64.00
Current: 49.300
Low
50.00
Averages
55.93
High
64.00
About TFC
Truist Financial Corporation is a financial services company. As a commercial bank, it offers a range of products and services through its wholesale and consumer businesses, including consumer and small business banking, commercial banking, corporate and investment banking, wealth management, payments, and specialized lending businesses. Its segments include Consumer and Small Business Banking (CSBB) and Wholesale Banking (WB). CSBB segment serves retail, premier, and small business clients, providing transaction, money market, savings, time deposits and payment services, credit cards, loans, and mortgages through digital banking, a network of community banking branches, ATMs, virtual service centers, and other channels. WB segment provides a comprehensive set of products, solutions, and advisory services to commercial, corporate, institutional and wealth clients. It also invests in certain affordable housing, new market tax credit, and renewable energy tax credit investments.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Truist Predicts Decline in Home Builder Revenue This Year, Yet Recommends These 4 Stocks for Purchase.
Home-builder revenue forecast: Home-builder revenue is expected to decline significantly in 2026 due to ongoing pressures in the housing market.
Investor opportunities: Despite the revenue drop, the situation presents a favorable opportunity for investors looking to target specific builders.
See More
Latest Ratings and Price Targets on Wall Street
- nLIGHT Coverage Initiation: Baird initiates coverage of nLIGHT with an Outperform rating and a $95 price target, citing favorable market trends and robust funding that support growth, particularly enhanced by the company's vertical integration and technological strengths.
- Apple's New Product Launch: Oppenheimer reiterates Apple as Perform, highlighting the new MacBook Pro lines powered by M5 Pro and M5 Max chips, which signify a new era of local AI computing and reinforce Apple's significant lead in efficiency and scalability in personal computing devices.
- PulteGroup and Toll Brothers Ratings: Truist initiates PulteGroup and Toll Brothers with Buy ratings, setting a price target of $170, as they believe the market is significantly undervaluing both companies' profitability potential, especially in the context of a recovering luxury housing market.
- Tesla and General Motors Upgrades: Bank of America upgrades Tesla to Buy with a $460 price target, viewing it as the leader in consumer autonomy, while reinstating General Motors as Buy, expecting benefits from lower warranty costs and regulatory credits.
See More
Truist Initiates Buy Rating on Toll Brothers with $190 Price Target
- Investment Rating Upgrade: Truist has initiated a buy rating on Toll Brothers with a $190 price target, indicating a 24% upside, reflecting strong market confidence in the company.
- Market Positioning Advantage: Analysts highlight that Toll Brothers' focus on the luxury home market differentiates it from competitors, and its higher price point has helped it achieve category leader status, suggesting continued stable performance.
- Future Growth Potential: Analysts believe that Toll Brothers will benefit from a rebound in the luxury home market in 2027, and its limited competition compared to low-end builders showcases its unique position in the market.
- Strong Stock Performance: Toll Brothers' shares have risen 14% this year and 42% over the past 12 months, indicating investor recognition of its long-term growth potential, especially amid the structural undersupply of homes in the U.S.
See More
BeOne Medicines AG Raises 2026 Revenue Guidance Amid Strong Q4 Results
- Significant Revenue Growth: BeOne Medicines AG reported global revenues of $1.5 billion for Q4 2025, reflecting a 33% increase from the previous quarter, while projecting $5.3 billion for 2026, a 40% year-over-year growth, indicating strong market performance and growth potential.
- Strong Brukinsa Performance: The company's lymphoma and leukemia treatment, Brukinsa, generated revenues of $1.1 billion and $3.9 billion for Q4 and the full year, respectively, marking increases of 38% and 49% from prior periods, further solidifying its market position in oncology.
- Analyst Price Target Increase: On February 27, Truist Securities raised its price target for BeOne Medicines AG from $400 to $412 while maintaining a Buy rating, reflecting confidence in the company's future growth, especially following the release of its fiscal 2026 revenue guidance.
- Market Expectation Pressure: Although the fiscal 2026 revenue guidance ranges from $6.2 billion to $6.4 billion, closely aligning with consensus estimates of $6.4 billion, analysts noted that this expectation has added pressure on the stock price, indicating a cautious market outlook on the company's future growth.
See More
Centene Named Among 14 Best GARP Stocks by Analysts
- Target Price Increase: Truist raised Centene's price target from $47 to $49 while maintaining a Buy rating, indicating analysts' optimism about the company's future growth, particularly after positive management meetings that highlighted confidence in profitability across various segments.
- Earnings Performance: In the Q4 2025 earnings report, Centene reported an adjusted diluted loss per share of $1.19; however, CEO Sarah London noted that the company slightly exceeded expectations shared in the third quarter, demonstrating resilience during a challenging year.
- Market Outlook: London anticipates that adjusted EPS for 2026 will exceed $3, representing over 40% year-over-year growth, which not only reflects stability in Medicaid and Marketplace segments but also indicates a rebuilding of the company's earnings strength.
- Business Diversification: Centene focuses on providing integrated services to government-sponsored and commercial healthcare programs, particularly for underinsured and uninsured individuals, with its diversified business model offering strong support for future growth.
See More
Nuvation Bio Expands SIGMA Study to Phase 3 Trial
- Clinical Trial Expansion: On February 9, Nuvation Bio announced a protocol amendment to the global SIGMA study, expanding it to a Phase 3 trial aimed at evaluating the efficacy of safusidenib for high-risk IDH1-mutant astrocytoma patients, highlighting the company's potential in oncology treatment.
- Expanded Patient Eligibility: The new protocol broadens patient eligibility in the registrational trial to include grades 2 and 3 IDH1-mutant astrocytoma patients with high-risk features, as well as grade 4 patients post-standard treatment, which is expected to significantly increase participant numbers and enhance the reliability of study outcomes.
- Price Target Increase: Truist raised Nuvation Bio's price target from $11 to $13 on January 27 while maintaining a Buy rating, reflecting strong market expectations for its Ibtrozi product line despite seasonal challenges.
- Diverse R&D Pipeline: Nuvation Bio is advancing several clinical-stage candidates, including a BET inhibitor and a ROS1 inhibitor, demonstrating its diversified strategy in oncology aimed at filling market gaps and enhancing the company's competitive edge.
See More
Truist Predicts Decline in Home Builder Revenue This Year, Yet Recommends These 4 Stocks for Purchase.
Home-builder revenue forecast: Home-builder revenue is expected to decline significantly in 2026 due to ongoing pressures in the housing market.
Investor opportunities: Despite the revenue drop, the situation presents a favorable opportunity for investors looking to target specific builders.
See More
Latest Ratings and Price Targets on Wall Street
- nLIGHT Coverage Initiation: Baird initiates coverage of nLIGHT with an Outperform rating and a $95 price target, citing favorable market trends and robust funding that support growth, particularly enhanced by the company's vertical integration and technological strengths.
- Apple's New Product Launch: Oppenheimer reiterates Apple as Perform, highlighting the new MacBook Pro lines powered by M5 Pro and M5 Max chips, which signify a new era of local AI computing and reinforce Apple's significant lead in efficiency and scalability in personal computing devices.
- PulteGroup and Toll Brothers Ratings: Truist initiates PulteGroup and Toll Brothers with Buy ratings, setting a price target of $170, as they believe the market is significantly undervaluing both companies' profitability potential, especially in the context of a recovering luxury housing market.
- Tesla and General Motors Upgrades: Bank of America upgrades Tesla to Buy with a $460 price target, viewing it as the leader in consumer autonomy, while reinstating General Motors as Buy, expecting benefits from lower warranty costs and regulatory credits.
See More
Truist Initiates Buy Rating on Toll Brothers with $190 Price Target
- Investment Rating Upgrade: Truist has initiated a buy rating on Toll Brothers with a $190 price target, indicating a 24% upside, reflecting strong market confidence in the company.
- Market Positioning Advantage: Analysts highlight that Toll Brothers' focus on the luxury home market differentiates it from competitors, and its higher price point has helped it achieve category leader status, suggesting continued stable performance.
- Future Growth Potential: Analysts believe that Toll Brothers will benefit from a rebound in the luxury home market in 2027, and its limited competition compared to low-end builders showcases its unique position in the market.
- Strong Stock Performance: Toll Brothers' shares have risen 14% this year and 42% over the past 12 months, indicating investor recognition of its long-term growth potential, especially amid the structural undersupply of homes in the U.S.
See More
BeOne Medicines AG Raises 2026 Revenue Guidance Amid Strong Q4 Results
- Significant Revenue Growth: BeOne Medicines AG reported global revenues of $1.5 billion for Q4 2025, reflecting a 33% increase from the previous quarter, while projecting $5.3 billion for 2026, a 40% year-over-year growth, indicating strong market performance and growth potential.
- Strong Brukinsa Performance: The company's lymphoma and leukemia treatment, Brukinsa, generated revenues of $1.1 billion and $3.9 billion for Q4 and the full year, respectively, marking increases of 38% and 49% from prior periods, further solidifying its market position in oncology.
- Analyst Price Target Increase: On February 27, Truist Securities raised its price target for BeOne Medicines AG from $400 to $412 while maintaining a Buy rating, reflecting confidence in the company's future growth, especially following the release of its fiscal 2026 revenue guidance.
- Market Expectation Pressure: Although the fiscal 2026 revenue guidance ranges from $6.2 billion to $6.4 billion, closely aligning with consensus estimates of $6.4 billion, analysts noted that this expectation has added pressure on the stock price, indicating a cautious market outlook on the company's future growth.
See More
Centene Named Among 14 Best GARP Stocks by Analysts
- Target Price Increase: Truist raised Centene's price target from $47 to $49 while maintaining a Buy rating, indicating analysts' optimism about the company's future growth, particularly after positive management meetings that highlighted confidence in profitability across various segments.
- Earnings Performance: In the Q4 2025 earnings report, Centene reported an adjusted diluted loss per share of $1.19; however, CEO Sarah London noted that the company slightly exceeded expectations shared in the third quarter, demonstrating resilience during a challenging year.
- Market Outlook: London anticipates that adjusted EPS for 2026 will exceed $3, representing over 40% year-over-year growth, which not only reflects stability in Medicaid and Marketplace segments but also indicates a rebuilding of the company's earnings strength.
- Business Diversification: Centene focuses on providing integrated services to government-sponsored and commercial healthcare programs, particularly for underinsured and uninsured individuals, with its diversified business model offering strong support for future growth.
See More
Nuvation Bio Expands SIGMA Study to Phase 3 Trial
- Clinical Trial Expansion: On February 9, Nuvation Bio announced a protocol amendment to the global SIGMA study, expanding it to a Phase 3 trial aimed at evaluating the efficacy of safusidenib for high-risk IDH1-mutant astrocytoma patients, highlighting the company's potential in oncology treatment.
- Expanded Patient Eligibility: The new protocol broadens patient eligibility in the registrational trial to include grades 2 and 3 IDH1-mutant astrocytoma patients with high-risk features, as well as grade 4 patients post-standard treatment, which is expected to significantly increase participant numbers and enhance the reliability of study outcomes.
- Price Target Increase: Truist raised Nuvation Bio's price target from $11 to $13 on January 27 while maintaining a Buy rating, reflecting strong market expectations for its Ibtrozi product line despite seasonal challenges.
- Diverse R&D Pipeline: Nuvation Bio is advancing several clinical-stage candidates, including a BET inhibitor and a ROS1 inhibitor, demonstrating its diversified strategy in oncology aimed at filling market gaps and enhancing the company's competitive edge.
See More
